We helped our client, a world-leading biotech company, establish a differentiated CI strategy to support in-market excellence across the US and EU
The Opportunity:
“What are the threats, opportunities and considerations to ensure differentiation and excellence in CAR-T Access across US and EU in the short, mid and long-term?”
To support a launched CAR-T product, our client sought to identify disruption and predict future scenarios to redefine their market access strategy and create a roadmap to success.
Our Approach:
Eradigm partnered with senior leaders across multiple cross-functional teams, including value, access and evidence generation business units. We developed a robust research framework, comprising of comprehensive primary and secondary methodologies to identify short, mid, and long-term opportunities and threats to the client’s business model. Taking an iterative approach to research, we were able to continuously contextualize competitor insights and develop a strategic playbook that enabled the client to redefine their market access strategy and create a roadmap to success across the US and EU markets.
Eradigm’s thorough identification and assessment of impacts included deep dives into the future of best-in-class customer experience for customers and patients, the current and emergent opportunities for optimal value recognition by payers and paradigm shifts shaping the future of CAR-T market access. By helping our client think cross-functionally and focus on long-term impact, we were able to facilitate critical dialogue on a global corporate market access strategy.
The Impact:
By harnessing our holistic expertise in CAR-T commercialization and market access, we proactively identified key trends and engaged our expert payer network with strategic inquiries. This enabled us to accurately forecast market reactions across short, medium, and long-term horizons, driving informed decision-making and positioning us as leaders in navigating future market dynamics. The project helped an established biotech become a world-leading presence in CAR-T, helping to shape an innovative global market access strategy. This project also built on Eradigm’s specialist knowledge in cell and gene therapy, marrying granular detail with bigger-picture strategic analysis.
